Niche Market Focus Acasti specializes in developing therapies for rare and orphan diseases such as Subarachnoid Hemorrhage and Ataxia Telangiectasia, which presents opportunities to target highly underserved patient populations with limited treatment options.

Orphan Drug Exclusivity With all three lead assets granted Orphan Drug Designation by the FDA, Acasti benefits from seven years of exclusive marketing rights in the U.S., making their products attractive for partners seeking protected market entry.

Recent Strategic Asset Sale The sale of krill-related patents and assets to Aker BioMarine for $3.1M indicates potential for partnerships or licensing opportunities related to novel bioresources and marine-derived compounds.

Pipeline Advancement & Collaborations Acasti is progressing towards pivotal Phase 3 trials for GTX-104 and has aligned with FDA, signaling readiness for commercialization and potential business opportunities in clinical development and commercialization support.

Financial Strength & Funding With a recent $7.5M private placement and a funding total of $10M, Acasti demonstrates solid financial backing, enabling expansion of sales efforts and partnership development in specialized therapeutic areas.